Gilead’s Kite taps Eisai vet to helm CAR-T commercial strategy by Arlene Weintraub Tuesday, July 10, 2018 Eisai and Celgene veteran Michael Amoroso will take on the challenge of making Gilead's entrance into CAR-T cancer treatments a success.
Lonza moves cell work, cuts jobs at plant hit by warning letter by Eric Palmer Monday, March 5, 2018 The decision by Lonza to move cell-therapy work out of a U.S. facility that was hit by an FDA warning letter will cost the plant about 125 jobs.
FiercePharmaAsia—Astellas, Celltrion, Korea's digital health plan by Angus Liu Friday, February 16, 2018 Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.
Biotech vets weigh in on getting drugs through Gottlieb’s FDA by Arlene Weintraub Wednesday, September 27, 2017 New FDA commissioner Scott Gottlieb will build on progress the FDA was making in facilitating faster drug approvals, three biotech execs predicted.
Oxford BioMedica and Novartis build on cell therapy supply deal by Eric Palmer Thursday, July 6, 2017 Oxford BioMedica has a new deal for up to $100 million to provide the lentiviral vectors for the personalized CAR-T treatment Novartis is developing.
